IVAX erhält von FDA Genehmigung für Krebsmittel-Herstellung - 500 Beiträge pro Seite

[SieLeiBo]

IVAX (878177)(IVX) berichtet eben, daß die FDA ein zusätzliches
Verfahrung zur Herstellung eines mit TAXOL vergleichbaren
Medikamentes genehmigt hat.
Taxol wird von Bristol-Myers vertrieben mit einem Jahresumsatz
von mehr als 1 Milliarde $!!
Taxol ist somit das umsatzstärkste Cancerostatikum.
IVAX hat seit Oktober 2000 ein injezierbares TAXOL-Äuivalent
im Markt (das einzige in den USA), welches bisher für 120 Mill.
$ verkauft wurde.
Mit der heutigen Mitteilung wird die Basis zur Herstellung
dieses Taxol-Äqivalentes erweitert, was die Geschäfte dieser
Pharmafirma deutlich beleben wird.

MfGr SieLeiBo

[Guru-Schreck]

Und wieso reagiert dann der Aktienkurs nicht darauf ?
Alles schon eingepreist ?

[SieLeiBo]

Eben bemerke ich, daß IVAX im Moment in den USA nicht gehandelt
wird. Gründe habe ich noch nicht gelesen.
Vielleicht hängt das mit der obigen Nachricht zusammen.
Oder es gibt eine weitere kursrelevante Nachricht.
Wenn man sich über IVAX informiert, sind durchweg bei
diesem Generica-Hersteller positive Daten zu finden.
- kürzlich wurden für alle Quartale bis Ende 2002
die Ergebnisse angeboben
- Das P/EG-Ratio beträgt günstige 1,11 (der vergleichbare
Sektor jedoch nur 1,96)
- Die Ergebnis-Schätzungen für die nächsten 5 Jahre be-
tragen betragen 27,5% (pro Jahr)
- Die Firma zahlt Dividente.
- Das KGV beträgt etwa 35
- Vor wenigen Tagen wurde der größte chilenische Pharma-
Hersteller übernommen
- alle Analysteneinschätzungen sind positiv.

Kurzum diese Aktie verspricht überdurchschnittliches
Potential.

MfGr SieLeiBo

[SieLeiBo]

Es kommt Bewegung in den Kurs.
Bö Ffm erhöht Bid und Ask deutlich auf 37,- /39,-.
Amerikaner wachen offenbar auf.

[SieLeiBo]

Der Handel wurde verspätet begonnen.
Kurs +8,5% auf 32,30 $
Bereits 3/4 Mill. Umsatz.
Schaut euch Ivax an und bildet Euch
ein Urteil

SieLeiBo

[SieLeiBo]

IVAX strebt weiter gen Norden.
Aktuell: 32,76$ (+10,5%)
Umsatz 2,2 Mill.
ATH 42,36$.
Bezogen auf den Dollar-Kurs ist die Aktie
in Ffm noch rel. günstig.
Überlege einen Nachkauf.
Was meint Ihr?

MfGr SieLeiBo

[Guru-Schreck]

Wednesday May 30, 10:03 am Eastern Time

Ivax says to launch LabChile tender Thursday

SANTIAGO, Chile, May 30 (Reuters) - Generic drug maker Ivax Corp. (AMEX:IVX - news) will launch its $395 million cash tender offer for 100
percent of Chile`s No. 1 pharmaceutical firm Laboratorio Chile SA (NYSE:LBC - news) on Thursday, Ivax`s Chilean subsidiary said on Wednesday.

The offer, aimed at boosting Ivax`s presence in South America, will be launched simultaneously in Chile and the United States at 9:00 a.m. local time
(1300 GMT) on May 31 and runs until noon (1600 GMT) on June 29, the subsidiary, Inversiones Glaciar I Limitada, said in a full-page advertisement
in Chilean daily El Mercurio.

Miami-based Ivax announced on May 21 it had agreed to pay $1.25 a share, or $25 per American depositary receipt, for the Chilean company under the tender offer.

The acquisition of Laboratorio Chile, which is also one of the biggest drug companies in Argentina and Peru, will expand Ivax`s distribution network throughout Latin America.
Laboratorio Chile had $173 million in revenues in 2000.

Ivax aims to become a big player in Latin America. It already has companies in Argentina, Mexico, Peru, Uruguay and Venezuela. Ivax has said the acquisition of Laboratorio Chile will
immediately add to its earnings.

[SieLeiBo]

IVAX steigt auch heute wieder bei hohen Umsätzen
auf derzeit 34,90 $. Es scheint, daß der Kurs
noch nicht ausgereizt ist.

MfGr SieLeiBo

[Guru-Schreck]

Friday June 8 11:56 AM ET

IVAX to Get Patent for Oral Paclitaxel

NEW YORK (Reuters) - Generic drug maker IVAX Corp.
(AMEX:IVX - news) said on Friday that U.S. regulators would issue
the firm a patent covering the oral form of widely used cancer drug
paclitaxel, which is normally administered through injection.

IVAX has been selling paclitaxel in the injected form since the fall of
2000, when Bristol-Myers Squibb Co.`s (NYSE:BMY - news)
exclusivity over the drug ended after a lengthy court battle between the
two firms.

IVAX is testing the oral formulation in patients with non-small cell lung
cancer, breast cancer and stomach cancer. The tests are currently in the
Phase II stage, but IVAX said it expects to expand the program to
include Phase III trials, typically the last stage before submitting an
application for approval.

The patent, which will be ``allowed`` by the U.S. Patent and Trademark
Office, covers ``formulations and methods that make it possible to
administer orally therapeutic agents such as paclitaxel and other agents
that are normally administered by injection or infusion,`` IVAX said.

Bristol-Myers sells paclitaxel under the brand name Taxol and
generated sales of $1.59 billion from the drug last year, making it the
top-selling cancer treatment.

IVAX sold about $85 million of the drug in its first two quarters
marketing its generic version, called Onxol.

A spokesman for IVAX said the patent strengthens the company`s
portfolio of cancer patents.

Shares of IVAX were up $1.40, or 3.77 percent, to $38.50 on the
American Stock Exchange in Friday midday trading.

[Guru-Schreck]

Monday June 11, 9:22 am Eastern Time

Press Release

IVAX to Begin Phase II Study On New Drug for Benign Prostatic Hypertrophy

MIAMI--(BUSINESS WIRE)--June 11, 2001--IVAX Corporation (AMEX:IVX - news) announced today that its Hungarian subsidiary, the IVAX Institute for Drug Research,
received approval to conduct a multi-center placebo-controlled human phase II study of its new molecule, GYKI-16084, in men with benign prostatic hypertrophy (BPH). It is
anticipated that 200 patients will be enrolled in the study, which will last 58 days.

In March 2001, IVAX announced the award of US Patent 6,194,411 for its proprietary compound, GYKI-16084, to be used in the study. Phase I studies distinguished the IVAX
compound as more uroselective, with a greatly reduced incidence of important side effects such as dizziness, fainting and sexual dysfunction, typical of the currently used drugs.

``This important new drug to treat BPH appears to be quite efficacious but less likely to cause the serious and common side effects associated with the presently available drugs,`` said
Phillip Frost, M.D., chairman and chief executive officer of IVAX.

IVAX Corporation, headquartered in Miami, is engaged in the research, development, manufacture and marketing of branded and brand equivalent pharmaceuticals and veterinary and
diagnostic products in the U.S. and international markets.

Except for the historical matters contained herein, statements in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties which may affect the company`s business and prospects, including
the risks that IVAX may not succeed in developing the GYKI-16084 product; that its patents pertaining to this product may be invalidated or may otherwise not succeed in preventing
the marketing of products generically equivalent to GYKI-16084; that IVAX may not be able to enroll the required number of patients in the phase II trial of GYKI-16084; that the trial
may not be completed in 58 days; that the clinical trials of GYKI-16084 may fail and may not generate data that would support the approval or marketing of this product for the
indications being studied or for other indications; that others may develop products for benign prostatic hypertrophy that are superior to the IVAX formulation; and other risks and
uncertainties based on economic, competitive, governmental, technological and other factors discussed in the Company`s annual report on form 10-K and its other filings with the
Securities and Exchange Commission.

[Guru-Schreck]

Thursday June 14, 8:58 pm Eastern Time

Ivax may be ripe for merger - report

NEW YORK, June 14 (Reuters) - Drug maker Ivax Corp. (AMEX:IVX - news) may be ripe for a takeover by drug giants AstraZeneca Plc (quote
from Yahoo! UK & Ireland: AZN.L) or GlaxoSmithKline Plc (quote from Yahoo! UK & Ireland: GSK.L), according to a report in Business Week magazine.

Ivax, which specializes in marketing generic versions of existing drugs, is also testing a promising immunotoxin drug for brain cancer, the report said.

Ivax said on Wednesday it expects second quarter earnings to exceed analysts` expectations, which it pegged at 25 cents per share, as tracked by research firm Thomson Financial/First
Call.

[Guru-Schreck]

uesday June 26, 9:46 am Eastern Time

Press Release

IVAX Enters Marketing Agreement for CFC-free Asthma Medicines in UK

MIAMI--(BUSINESS WIRE)--June 26, 2001--IVAX Corporation (AMEX:IVX - news) said that its subsidiary, IVAX
Pharmaceuticals UK, has entered into an agreement with the Italian group Chiesi Farmaceutici to copromote and distribute a
CFC-free formulation of beclomethasone and other asthma inhalation products in the UK. IVAX` patented Easi-Breathe®
inhaler and Chiesi`s patented beclomethasone CFC-free Modulite(TM) will be marketed as Beclazone Modulite(TM)
Easi-Breathe®.

``This partnership combines the marketing strengths of both companies in the UK,`` said Neil Flanzraich, vice chairman and
president of IVAX. ``IVAX` sales of products to treat asthma are already the third largest in the billion-dollar UK market.
IVAX` patented Easi-Breathe® inhaler is the leading breath-activated inhaler in the UK and is being sold in a number of other
countries.``

The IVAX UK sales force and Chiesi`s UK sales force will both promote the Beclazone Modulite(TM) Easi-Breathe® and
Beclazone Modulite(TM) (standard metered dose inhaler) as well as IVAX` Salamol CFC-free Easi-Breathe® product.

IVAX said that it has recently launched Easi-Breathe® products in the Czech Republic, the Slovak Republic and Russia.
IVAX has said previously that it expects worldwide sales of its asthma products to be over $1 billion by 2005. IVAX has also
initiated a website known as www.asthma4all.com as a resource for asthma patients and their families.

IVAX Corporation, headquartered in Miami, Florida, is engaged in the research, development, manufacturing and marketing of
branded and brand equivalent pharmaceuticals and veterinary and diagnostic products in the U.S. and international markets.

Except for historical matters contained herein, statements in this press release are forward-looking and are made pursuant to
the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that
forward-looking statements involve risks and uncertainties that may affect IVAX` business and prospects, including the risks
that the CFC-free beclomethasone product may not be approved for marketing in the UK; that once approved, it may not be
successfully commercialized; that the IVAX/Chiesi partnership may not strengthen IVAX` position in the UK asthma market;
that IVAX` sales of asthma products may not reach $1 billion by 2005; and other risks and uncertainties that may cause results
to differ materially from those set forth in the forward-looking statements. In addition to the risk factors set forth above,
investors should consider the economic, competitive, governmental, technological and other factors discussed in the
Company`s Annual Report on form 10K and other filings with the Securities and Exchange Commission.

[Boston1001]

Hallo,
IVAX ist für mich ein neuer Wert, den ich noch nicht lange kenne. Sind die 36,90 Euro ein Einstiegspreis oder sollte man noch warten? Kann da noch irgendetwas "im Busch " sein? Nergatives, meine ich.
MfG

[SieLeiBo]

Hallo,

nach dem Rückgang des Kurses vorige Woche legt IVAX (IVX)
gegen den Trend seit drei Tagen zu.
Der nachfolgende "letter" ist für die Beurteilung der Aktie
hilfreich.
IVAX ist eindeutig unterbewertet auf diesem Niveau.
Das ist keine Meinung aus dem Bauch! Es ist belegbar.

Bildet Euch selbst eine Meinung.

MfGr SieLeiBo


Tuesday August 14, 6:02 am Eastern Time

Press Release

SOURCE: IVAX Corporation

IVAX Distributes Letter To Shareholders

MIAMI--(BW HealthWire)--Aug. 14, 2001--IVAX Corporation (AMEX:IVX - news;
LSE:IVX.L) will distribute a letter to shareholders relating to recent corporate events. The text
of the letter to shareholders follows.

August 14, 2001

Dear Fellow Shareholders:

We are pleased to update you on recent items we consider to be of importance.

Brand Equivalent Paclitaxel

Sales of IVAX` injectable Onxol(TM) brand equivalent paclitaxel anti-cancer drug exceeded
$77 million in the second quarter of this year following more than $50 million in revenues in the
first quarter of 2001. IVAX` injectable paclitaxel is the brand equivalent to Bristol-Myers
Squibb Company`s Taxol®, the largest selling anti-cancer drug in the world with U.S. sales
well in excess of $1.0 billion in 2000.

We continue to believe in the strong growth prospects of our brand equivalent paclitaxel, even
though the FDA recently approved two other generic paclitaxel products. These regulatory
approvals had been expected for some time. Our confidence is based, in part, on IVAX`
considerable experience in this marketplace, extensive clinical testing, and enhanced supply and
production capacity. It is also important to point out that the branded product currently holds
approximately 70% market share, representing opportunity to further expand our market
penetration while providing space for other generic products.

- On August 13, 2001, we entered into a multi-year agreement to

supply our injectable Onxol brand equivalent paclitaxel

anti-cancer drug to Novation, the largest hospital supply chain

management company in the United States providing purchasing

solutions for more than 2,300 health care organizations, including

some of the most prestigious hospitals across the country. This

agreement to provide our lower-cost, brand equivalent paclitaxel

represents significant savings to hospitals and brings

cost-effective care to their patients. We expect to start

shipments during September. We have a long-standing relationship

with Novation and have been supplying its hospital members with an

extensive line of products for a variety of indications across

multiple therapeutic categories.

- IVAX has been marketing its injectable paclitaxel product since

October 2000, and has sold more than $160 million of this product.

Since gaining regulatory approval more than 10 months ago, over

5,000 people in the U.S. have been treated with our paclitaxel

product. This product has also received approval for various

indications in Canada (May 2000), Poland (March 2000), the

15-member states of the European Union (July 1999), and the Czech

Republic (March 1999).

- We believe our paclitaxel product to be the only brand equivalent

product to have undergone extensive pre-clinical, pharmacological

and clinical studies. At over 100 sites in North America, Europe

and Australia, more than 700 patients with non-small cell lung,

breast and ovarian cancer or AIDS-related Kaposi`s Sarcoma

participated in our clinical trials.

- In May 2001, production capacity for IVAX` paclitaxel was enhanced

when the FDA approved an additional supplier of the paclitaxel

active ingredient and contract manufacturer of the finished

product. Demand for our product continues to be very strong and

these additional sources of supply will permit us to serve an even

larger market segment.

As previously reported, we are developing a patented, oral dosage form of paclitaxel which is anticipated to be of substantial
benefit to patients as all presently marketed paclitaxel products, including IVAX` brand equivalent paclitaxel and the branded Taxol
product, are administered only by injection. Recently completed Phase II clinical trials for our oral form of paclitaxel have shown
anti-cancer activity in patients with advanced lung cancer. The results of these trials suggest that our oral paclitaxel, by itself, may
be as effective as various combinations of intravenous drugs currently used to treat lung cancer, but with greater convenience and
fewer side effects. We plan to conduct a Phase III clinical trial in which oral paclitaxel will be compared with standard
intravenous chemotherapy as an initial treatment of advanced lung cancer. Anti-cancer effects have also been seen in ongoing
Phase II studies for advanced breast cancer and advanced stomach cancer, and are expected to be reported when the full results
are available.

Second Quarter Earnings

IVAX Corporation achieved substantially better financial results for the second quarter of 2001 than in 2000. Net revenues
increased 63% to $301.8 million and earnings per share more than doubled to $.33 per share. Our continued growth over the last
few years has resulted from new product introductions as well as strategic acquisitions that provide earnings power and additional
distribution capabilities for our products.

For the second quarter of 2001, income from continuing operations was $67.9 million, or $.33 per diluted share, representing an
increase of 109% over the $32.5 million, or $.16 per diluted share, reported in the second quarter of 2000. Net revenues for the
second quarter of 2001 increased by 63.3% to $301.8 million as compared to net revenues of $184.8 million in the second quarter
of last year.

For the six months ended June 30, 2001, income from continuing operations rose by 116% to $128 million, or $.62 per diluted share,
versus income from continuing operations of $59.1 million, or $.29 per diluted share, for the same period a year earlier. Net
revenues for the first six months of 2001 advanced by 52.6% to $561.7 million compared to net revenues of $368.1 million in the
prior year.

In the second quarter, our investment in research and development increased by 17% over the prior year. For the current year, we
expect our R&D spending to be approximately $90 million, with about two-thirds dedicated to our proprietary pipeline of novel
compounds to treat various forms of cancer, multiple sclerosis, epilepsy, Parkinson`s disease, asthma, non-malignant prostate
enlargement, inflammatory bowel disease and cystic fibrosis. These products are in various stages of research and development.

Our gross profit margin improved to 52.5% of net revenues for the second quarter of 2001 compared to 48.5% in the second
quarter of 2000, primarily due to sales of IVAX` brand equivalent anti-cancer drug, paclitaxel. Excluding paclitaxel sales, second
quarter net revenues from other worldwide sales increased by 22% over the year ago period. Net revenues in North America
increased 103.7% while net revenues in Europe and Latin America increased 37.8%, but were decreased by a negative currency
impact just under 5%. Our increase in income from continuing operations was achieved despite a higher tax rate for the current
period compared to last year. We anticipate continued year-over-year increases in revenues and normal operating income for the
remainder of this year.

Resumption Of Share Repurchase Program

In response to the recent decline in stock price and our confidence in the company`s prospects for continued growth of our overall
business and, in particular, our brand equivalent paclitaxel anti-cancer product, we recently resumed the repurchase of shares
under our current split-adjusted 12.5 million share repurchase program authorized by IVAX` Board of Directors in August 2000.
During the past year, we repurchased approximately 4.2 million shares of our outstanding common stock on a split adjusted basis
and sold 5.1 million put options under this program, of which 1.4 million options are currently outstanding. Since February 1998, we
have repurchased 45.3 million shares of our outstanding common stock on a split-adjusted basis at an average price of $8.87 per
share. IVAX currently has approximately 201 million common shares outstanding.

Recent FDA Approvals

On July 27, 2001, we received FDA approval for over-the-counter (OTC) sales of our famotidine tablets USP in 10 mg strength
for the short-term prevention of heartburn and sour stomach. We immediately began marketing and shipping this product through
our wholly owned subsidiary, IVAX Pharmaceuticals, Inc. We expect our OTC famotidine 10 mg tablets to be one of only two
brand equivalent products with regulatory approval for immediate sale. With the addition of this product to the antacid category,
IVAX is currently the only manufacturer and store-brand distributor of all three major H2 blocker products: Cimetidine 200 mg
(generic equivalent of Tagamet®); Ranitidine 75 mg (generic equivalent of ZANTAC®); and Famotidine 10 mg (generic
equivalent of Pepcid AC®).

On August 8, 2001, we received FDA approval for our Abbreviated New Drug Application (ANDA) for sales of isosorbide
mononitrate extended-release tablets in 30 mg and 120 mg strengths. Previously, we received FDA approval for our isosorbide
mononitrate extended-release 60 mg tablets. Isosorbide mononitrate is used to treat angina due to coronary artery disease and is
the generic equivalent of Schering Corporation`s Imdur® tablets. We will sell this product through our wholly owned subsidiary,
IVAX Pharmaceuticals, Inc.

We have received six generic drug approvals so far this year - with 33 ANDAs and tentative approvals currently pending at the
FDA. We are continuing our aggressive filing schedule for new ANDA submissions.

Acquisition Of Laboratorio Chile S.A.

In July 2001, we successfully completed the acquisition of approximately 99.6% of the outstanding shares and the outstanding
American Depository Shares (``ADSs``) of Laboratorio Chile S.A. for approximately $394 million in cash. It is the largest Chilean
pharmaceutical company in revenue terms and also among the major pharmaceutical companies in Argentina and Peru. Lab Chile
manufactures, markets and sells a broad line of more than 900 branded and brand equivalent products in Chile, Argentina, Peru
and Bolivia. Its main products focus on the treatment of respiratory and infectious diseases and the company has strong franchises
in cardiovascular, neurological and gynecological products. This acquisition adds Chile to the growing IVAX Latin American
family, which already includes companies in Mexico, Venezuela, Peru, Argentina and Uruguay. Our continued growth in this
region is part of our previously announced strategy to increase our presence in rapidly growing markets such as Latin America,
Central and Eastern Europe and Asia. On July 31, 2001, pursuant to the requirements of Chilean and U.S. law, we commenced
simultaneous tender offers in the United States and Chile for the remaining .4% of the outstanding shares of Laboratorio Chile,
S.A.

Update On Respiratory Research And Development

IVAX continues to expand the international marketing of asthma drugs in various European countries leveraging its patented
Easi-Breathe® device, the top selling breath-activated device in the United Kingdom. The asthma medications, albuterol and
beclomethasone, are available in Easi-Breathe inhaler formats in both CFC and CFC-free formulations, while cromolyn sodium is
as yet available only in a CFC formulation. In addition, our metered-dose dry powder inhaler in albuterol and budesonide formats is
awaiting regulatory approval in Europe and will be marketed by a partner. Earlier this summer we also entered into an agreement
with the Italian group Chiesi Farmaceutici to co-promote and distribute a CFC-free formulation of beclomethasone and other
asthma inhalation products in the UK. Our Easi-Breathe inhaler and Chiesi`s patented beclomethasone CFC-free Modulite(TM)
will be marketed as Beclazone Modulite(TM) Easi-Breathe®.

For the U.S. market, IVAX has completed initial Phase III clinical trials which will support FDA submissions for our CFC-free
albuterol and beclomethasone in our Easi-Breathe and conventional metered-dose formats as well as for budesonide in our
metered-dose dry powder inhaler. However, additional Phase III trials to support each of these products will be required and are
either underway or in preparation. In that connection, we are currently in Phase III clinical trials for albuterol in CFC-free formats,
and expect to start certain additional Phase III clinical trials for beclomethasone in CFC-free formats in the fourth quarter of this
year. We also estimate commencing Phase III clinical trials for budesonide in our metered-dose dry powder inhaler in 2002. We
have a high degree of confidence in these clinical programs for our various respiratory products as they successfully completed
similar clinical testing overseas and are currently on the market in Europe or awaiting regulatory approval. We also believe our
respiratory business will continue to achieve significant growth over the coming years.

In addition, we expect to start separate Phase III clinical trials for our fluticasone nasal spray (brand equivalent to Flonase®) in
the third quarter of this year.

As a service to asthma patients worldwide and the physicians who treat them, we launched a Web site at www.asthma4all.com
that provides comprehensive, up-to-date information on this condition. This Web site features state of the art graphics as well as a
live news feed of developments relating to asthma, information about IVAX` products, links to other sources of information for
asthma sufferers, and a powerful search engine to explore these resources.

Brain Tumor Compounds

Our lead brain cancer compound, TP38, is currently in Phase I/II clinical trials at the Duke University Medical Center and the
University of California at San Francisco. These studies have yielded encouraging results that are expected to be reported in the
coming months. TP-38 is a highly potent medication, which unlike most experimental cancer treatments of malignant brain tumors,
is designed to kill cancer cells while leaving the normal brain cells unaffected.

In July 2001, our immunotoxin program with Duke University Medical Center was expanded to develop and market specific toxins
that bind to and destroy cells expressing the EGF receptor variant III (EGFRvIII). EGFRvIII is found on the surface of a high
percentage of cancers of the brain, breast, lung, and ovary and is not found on normal cells. The absence of this receptor on
healthy cells makes EGFRvIII a very attractive potential target for directed toxin therapy of a wide range of tumors of the brain
and other parts of the body.

Appointment of Director of Investor Relations and Corporate Communications

In July 2001, Howard A. Goldman joined the company as director of investor relations and corporate communications. Mr.
Goldman will be responsible for communications with the global investment community, media and IVAX` employees. He has
more than 17 years of comprehensive investor and communications experience - including the medical diagnostics, pharmaceutical
and healthcare sectors - serving public and private companies from corporate and consulting situations. He also was in television
news for four years as a broadcast journalist, producer and on-camera anchor. Mr. Goldman received his Master`s of Science
degree and Bachelor of Science degree in Communication from Illinois State University. In addition, he is the current president of
the South Florida Chapter of NIRI (National Investor Relations Institute) and has been an officer and board member of this
professional organization since 1998.

We plan to update you from time to time. IVAX has been enjoying excellent results in recent years and we expect our progress to
continue.

Sincerely,

[SieLeiBo]

IVAX (IVX) bleibt ein aussichtsreiches Investment
im Pharmabereich.
Die fundamentale Unterbewertung ist offensichlich.
In den letzten Tagen hat IVAX relative Stärke
gezeigt.
Ich kann leider den Vergleichs-Chart nicht zeigen.
Seht es Euch im 3 Mon. und 1 Jahres-Vergleich an (z.B. über
Yahoo).
Auf die fundamentale Unterbewertung gehe ich in den nächsten
Tagen näher ein.
http://quote.yahoo.com/q?s=^BTK&d=c&k=c1&c=ivx,^spc,^ixic,
^dji&a=v&p=s&t=3m&l=on&z=m&q=lq?s=^BTK&d=c&k=c1&c=ivx,^spc,^ixic,
^dji&a=v&p=s&t=3m&l=on&z=m&q=l

MfGr SieLeiBo

[SieLeiBo]

IVAX (IVX) wird heute von CIBC Worl Mkts. (Elliot Wilbur)
als Kauf mit KZ 48$ empfohlen.
Heutiger Kurs ca. 33,80$.
Diese Empfehlung ist für mich nachvollziehbar.

MfGr SieLeiBo

[SieLeiBo]

IVAX übertrifft Analystenerwartungen und
steigert Gewinn zu Vorjahresquartal deutlich (ca.100%)

Quelle:
Thursday October 25, 7:22 am Eastern Time

Ivax profits double on respiratory drugs, Taxol copy

NEW YORK, Oct 25 (Reuters) - Generic drugmaker Ivax Corp. (AMEX:IVX - news) said
on Thursday its third-quarter profits doubled, fueled by sales of respiratory treatments and a
copycat form of popular cancer drug Taxol.

The Miami-based firm posted earnings of $61.5 million, or 30 cents per share, compared with $30.9 million, or 15 cents per
share, in the year-ago period.

Analysts on average projected Ivax would earn 26 cents per share, with estimates ranging from 23 cents to 28 cents per share,
according to Thomson Financial/First Call.

Net revenues soared to $322 million from $182.6 million.

The company said on Sept. 20 it expected sales from the generic form of Taxol, known as paclitaxel, to drop from the second
quarter because of shipping problems and increased competition.